Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2016

01-03-2016 | Research Article

The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy

Authors: R. Mazzola, S. Fersino, A. Fiorentino, F. Ricchetti, N. Giaj Levra, G. Di Paola, G. Sicignano, S. Naccarato, R. Ruggieri, F. Alongi

Published in: Clinical and Translational Oncology | Issue 3/2016

Login to get access

Abstract

Purpose

To analyze clinical-dosimetric predictors of genitourinary (GU) toxicity in a cohort of prostate cancer (PC) patients treated with moderate hypofractionation and simultaneous integrated boost (SIB) using volumetric modulated arc therapy (VMAT) technique.

Materials and methods

60 patients were selected. Patients were stratified into low (43 %), intermediate (30 %) and high-risk (27 %) groups. Low-risk patients received 73.5 Gy to PTV1; intermediate-risk received 73.5 Gy to PTV1 and 60 Gy to PTV2; high-risk received 73.5 Gy to PTV1, 60 Gy to PTV2, and 54 Gy to PTV3. All patients were treated in 30 fractions. Androgen deprivation therapy (ADT) was prescribed upfront in intermediate and high-risk categories. Toxicity was scored according to Common Terminology Criteria for Adverse Events v4.0 scoring system.

Results

Median follow-up was 30 months (range 16–36 months). GU acute toxicity was recorded as followS: G0 = 16/60 (27 %), G1 = 18/60 (30 %); G2 = 26/60 (43 %). GU late toxicity was recorded as follows: G0 = 20/60 (34 %); G1 = 29/60 (48 %); G2 = 11/56 (18 %). The risk of acute G2 GU toxicity was three times higher for prostate volume ≥80 cc. In 60 % of the patients with a prostate volume ≥80 cc, the first 3 weeks are at particular risk for toxicity onset. In the late setting, no statistical significance was found between GU toxicity and prostate gland dimension.

Conclusion

Prostate volume ≥80 cc resulted a predictive factor of acute G2 GU toxicity, in moderate hypofractionation and volumetric modulated arc radiation therapy for definitive PC.
Literature
1.
Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78:11–8.CrossRefPubMed
2.
Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23:6132–8.CrossRefPubMed
3.
Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnarò P, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84:1172–8.CrossRefPubMed
4.
Kuban DA, Nogueras-Gonzalez GM, Hamblin L. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys. 2010;78:S58–9.CrossRef
5.
Alongi F, Fogliata A, Navarria P, Tozzi A, Mancosu P, Lobefalo F, et al. Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Strahlenther Onkol. 2012;188(11):990–6.CrossRefPubMed
6.
Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31:3860–8.PubMedCentralCrossRefPubMed
7.
Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys. 2011;81:1271–8.CrossRefPubMed
8.
Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13:43–54.CrossRefPubMed
9.
Alongi F, Cozzi L, Fogliata A, Iftode C, Comito T, Clivio A, et al. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. Anticancer Res. 2013;33(10):4537–43.PubMed
10.
Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, et al. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:392–8.CrossRefPubMed
11.
Ferrera G, Mortellaro G, Mannino M, Caminiti G, Spera A, Figlia V, et al. Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales. Radiol Med. 2015.
12.
Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13.CrossRefPubMed
13.
Pedicini P, Caivano R, Strigari L, Benassi M, Fiorentino A, Fusco V, In regard to Miralbell, et al. Re: dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys. 2013;85(1):10–1.CrossRefPubMed
14.
De Bari B, Fiorentino A, Arcangeli S, Franco P, D’Angelillo RM, Alongi F. From radiobiology to technology: what is changing in radiotherapy for prostate cancer. Expert Rev Anticancer Ther. 2014;14(5):553–64.CrossRefPubMed
15.
De Bari B, Fiorentino A, Greto D, Ciammella P, Arcangeli S, Avuzzi B, et al. Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. Tumori. 2013;99(6):637–49.PubMed
16.
17.
Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys. 2007;67(5):1401–10.CrossRefPubMed
18.
Le H, Rojas A, Hughes R, Ostler P, Lowe G, Bryant L, et al. The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;87(2):270–4.CrossRefPubMed
19.
Monroe AT, Faricy PO, Jennings SB, Biggers RD, Gibbs GL, Peddada AV. High-dose-rate brachytherapy for large prostate volumes (> or 50 cc): uncompromised dosimetric coverage and acceptable toxicity. Brachytherapy. 2008;7:7–11.CrossRefPubMed
20.
Krupski T, Bissonette EA, Petroni GR, Theodorescu D. The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. Eur Urol. 2003;43:467–72.CrossRefPubMed
21.
Sherertz T, Wallner K, Wang H, Sutlief S, Russell K. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys. 2001;51:1241–5.CrossRefPubMed
22.
Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nussen S, et al. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):83–9.CrossRefPubMed
23.
Aizer AA, Anderson NS, Oh SC, Yu JB, McKeon AM, Decker RH, et al. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011;79(2):379–84.CrossRefPubMed
24.
Akin M, Oksuz DC, Iktueren B, Ambarcioglu P, Karacam S, Koca S, et al. Does rectum and bladder dose vary during the course of image-guided radiotherapy in the postprostatectomy setting? Tumori. 2014;100(5):529–35.PubMed
25.
D’Angelillo RM, Franco P, De Bari B, Fiorentino A, Arcangeli S, Alongi F. Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era. Critical Rev Oncol Hematol. 2015;93:136–48.CrossRef
26.
Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology. 1997;49:38–45.CrossRefPubMed
27.
Roach M 3rd, Faillace-Akazawa P, Malfatti C, Holland J, Hricak H. Prostate volumes defined by magnetic resonance imaging andcomputerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;35:1011–8.CrossRefPubMed
28.
Villeirs GM, Van Vaerenbergh K, Vakaet L, Bral S, Claus F, De Neve WJ, et al. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol. 2005;181:424–30.CrossRefPubMed
29.
De Bari B, Alongi F, Lestrade L, Giammarile F. Choline-PET in prostate cancer management: the point of view of the radiation oncologist. Crit Rev Oncol Hematol. 2014;91:234–47.CrossRefPubMed
30.
Alongi F, Fersino S, Giaj Levra N, Mazzola R, Ricchetti F, Fiorentino A, et al. Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy. Clin Nucl Med. 2015.
Metadata
Title
The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy
Authors
R. Mazzola
S. Fersino
A. Fiorentino
F. Ricchetti
N. Giaj Levra
G. Di Paola
G. Sicignano
S. Naccarato
R. Ruggieri
F. Alongi
Publication date
01-03-2016
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 3/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1371-2

Other articles of this Issue 3/2016

Clinical and Translational Oncology 3/2016 Go to the issue

Review Article

The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer

Research Article

Shorter hemodialysis duration is a risk factor for the recurrence of urothelial carcinoma of the bladder in patients on maintenance hemodialysis

Research Article

Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis

Review Article

Central nervous system niche involvement in the leukemia

Research Article

Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients

Research Article

Methylation of ASC/TMS1 promoter is associated with poor prognosis of patients with gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits